Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOACs versus warfarin for left ventricular thrombus
ACTRN12618001254280Phase 4Recruiting
- Sponsor
- Auckland District Health Board
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of warfarin, apixaban, rivaroxaban and dabigatran in Left ventricular thrombosis (LVT) (2 arms), sponsored by Auckland District Health Board. Primary endpoint: Primary composite endpoint. Started Oct 2018; status: recruiting.
02
Drugs
warfarinapixabanrivaroxabandabigatran
03
Conditions
Left ventricular thrombosis (LVT)
Beyond the preview
Go deeper on ACTRN12618001254280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001254280.